POLISCOPE
Back to feed
NewsSan Diego Business JournalAugust 17, 2026San Diego

BlossomHill Therapeutics raises $150 million in Nasdaq initial public offering

BlossomHill Therapeutics launched its initial public offering on the Nasdaq stock exchange on August 7, raising $150 million. The company plans to use the capital to support late-stage clinical studies for its lead lung cancer drug candidate, expected to begin as early as next year.

biotechnologystock marketoncologyclinical trialsbusiness
Read the full story at San Diego Business Journal

Why It Matters

The company's transition to a public entity provides it with $150 million in new capital to fund the development and clinical testing of its oncology and immunology drug pipeline.

Key Facts

  • BlossomHill Therapeutics raised $150 million through an upsized initial public offering.
  • The company began trading on the Nasdaq stock exchange on August 7.
  • The company's ticker symbol is 'BLSM'.
  • The company is developing a lead lung cancer drug candidate.
  • Late-stage clinical studies for the lead drug candidate are scheduled to begin as early as next year.

Who's Mentioned

otherBLSM“Ticker symbol for BlossomHill Therapeutics”personY. Peter Li“Co-founder, Chairman, and CEO of BlossomHill Therapeutics.”personJ. Jean Cui“President and CEO of BlossomHill Therapeutics.”organizationBlossomHill Therapeutics“Precision oncology and immunology medicine company based in San Diego.”organizationNasdaq“Stock exchange where BlossomHill debuted.”personGeoff Oxnard“Executive Vice President and Chief Medical Officer of BlossomHill Therapeutics.”